{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:25:44Z","timestamp":1778797544616,"version":"3.51.4"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2024ZD0522806"],"award-info":[{"award-number":["2024ZD0522806"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370096"],"award-info":[{"award-number":["82370096"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172728"],"award-info":[{"award-number":["82172728"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010246","name":"Postdoctoral Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["2018K049A"],"award-info":[{"award-number":["2018K049A"]}],"id":[{"id":"10.13039\/501100010246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2018M643891"],"award-info":[{"award-number":["2018M643891"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2019T120971"],"award-info":[{"award-number":["2019T120971"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["45786"],"award-info":[{"award-number":["45786"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20242092"],"award-info":[{"award-number":["BK20242092"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.critrevonc.2025.104717","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T10:39:07Z","timestamp":1744022347000},"page":"104717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Novel bioengineered drugs with immunotherapies for malignant pleural effusion: Remodulate tumor immune microenvironment and activate immune system"],"prefix":"10.1016","volume":"211","author":[{"given":"Lu","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YuTing","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SuHua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tangfeng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104717_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2019.09.018","article-title":"Recent advances on thermosensitive and pH-sensitive liposomes employed in controlled release","volume":"315","author":"Abri Aghdam","year":"2019","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jconrel.2009.10.003","article-title":"Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice","volume":"142","author":"Al-Abd","year":"2010","journal-title":"J. Control Release"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s40425-019-0590-4","article-title":"Treatment of malignant pleural effusions: the case for localized immunotherapy","volume":"7","author":"Albert","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"S1","key":"10.1016\/j.critrevonc.2025.104717_bib4","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.25.1_supplement.1036.3","article-title":"Barrier function of human pleura mesothelium is constituted by tight junctions","volume":"25","author":"Amasheh","year":"2011","journal-title":"Faseb J."},{"key":"10.1016\/j.critrevonc.2025.104717_bib5","doi-asserted-by":"crossref","unstructured":"Amasheh, S., M. Fromm, and D. G\u00fcnzel, Claudins of intestine and nephron \u2013 a correlation of molecular tight j unction structure and barrier function. Acta Physiologica. 201(1): p. 133-140.","DOI":"10.1111\/j.1748-1716.2010.02148.x"},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104717_bib6","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr. Biol."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104717_bib7","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104717_bib8","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/bjc.2017.356","article-title":"TAMeless traitors: macrophages in cancer progression and metastasis","volume":"117","author":"Aras","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/0008-5472.CAN-14-3619","article-title":"Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors","volume":"76","author":"Baird","year":"2016","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104717_bib10","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nri3921","article-title":"STING: infection, inflammation and cancer","volume":"15","author":"Barber","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104717_bib11","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab after completion of locally ablative therapy for oligometastatic non\u2013small cell lung cancer: a phase 2 trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104717_bib12","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1432-1033.1993.tb18261.x","article-title":"Identification and characterization of a soluble form of the plasma cell membrane glycoprotein PC-1 (5\u2032-nucleotide phosphodiesterase)","volume":"217","author":"Belli","year":"1993","journal-title":"Eur. J. Biochem."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104717_bib14","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ni.1937","article-title":"Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm","volume":"11","author":"Biswas","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104717_bib15","doi-asserted-by":"crossref","first-page":"2438598","DOI":"10.1155\/2018\/2438598","article-title":"Natural killer cells from malignant pleural effusion are endowed with a decidual-like proangiogenic polarization","volume":"2018","author":"Bosi","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.critrevonc.2025.104717_bib16","doi-asserted-by":"crossref","first-page":"2438598","DOI":"10.1155\/2018\/2438598","article-title":"Natural killer cells from malignant pleural effusion are endowed with a decidual-like proangiogenic polarization","volume":"2018","author":"Bosi","year":"2018","journal-title":"J. Immunol. Res."},{"issue":"26","key":"10.1016\/j.critrevonc.2025.104717_bib17","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104717_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104717_bib19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1378\/chest.110.2.433","article-title":"Elevation of interleukin-10 levels in malignant pleural effusion","volume":"110","author":"Chen","year":"1996","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104717_bib20","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1164\/rccm.200504-588OC","article-title":"CD4+CD25+\u2009regulatory T lymphocytes in malignant pleural effusion","volume":"172","author":"Chen","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"7637","key":"10.1016\/j.critrevonc.2025.104717_bib21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104717_bib22","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ni.3398","article-title":"Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis","volume":"17","author":"Cheng","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104717_bib23","doi-asserted-by":"crossref","first-page":"1112960","DOI":"10.3389\/fimmu.2023.1112960","article-title":"Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma","volume":"14","author":"Chintala","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104717_bib24","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jconrel.2022.10.002","article-title":"Glycosylation of OVA antigen-loaded PLGA nanoparticles enhances DC-targeting for cancer vaccination","volume":"351","author":"Chou","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2025.104717_bib25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.lungcan.2020.10.007","article-title":"Oncolytic herpesvirus therapy for mesothelioma \u2013 a phase I\/IIa trial of intrapleural administration of HSV1716","volume":"150","author":"Danson","year":"2020","journal-title":"Lung Cancer"},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104717_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176178","article-title":"Characteristics of malignant pleural effusion resident CD8(+) T cells from a heterogeneous collection of tumors","volume":"21","author":"Dhupar","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104717_bib27","first-page":"486","article-title":"[Treatment of malignant effusions with the injection of dendritic cells derived from autologous peripheral CD34+ stem cells]","volume":"40","author":"Di","year":"2008","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104717_bib28","first-page":"163","article-title":"Establishment of a malignant pleural effusion mouse model: pathogenesis pathways","volume":"1","author":"Domvri","year":"2012","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104717_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.676702","article-title":"PTX3 regulation of inflammation, hemostatic response, tissue repair, and resolution of fibrosis favors a role in limiting idiopathic pulmonary fibrosis","volume":"12","author":"Doni","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104717_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.846235","article-title":"Localized intra-cavitary therapy to drive systemic anti-tumor immunity","volume":"13","author":"Donnenberg","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104717_bib31","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.1016\/j.jtcvs.2020.11.160","article-title":"Intrapleural interleukin-2-expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease","volume":"163","author":"Ekeke","year":"2022","journal-title":"J. Thorac. Cardiovasc Surg."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104717_bib32","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1002\/eji.201041037","article-title":"IL-1\u03b2 regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function","volume":"40","author":"Elkabets","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104717_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114296","article-title":"Progress of engineered bacteria for tumor therapy","volume":"185","author":"Fan","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.critrevonc.2025.104717_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216777","article-title":"Engineered lactococcus lactis intrapleural therapy promotes regression of malignant pleural effusion by enhancing antitumor immunity","volume":"588","author":"Fan","year":"2024","journal-title":"Cancer Lett."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104717_bib35","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1021\/nn900785b","article-title":"Honokiol nanoparticles in thermosensitive hydrogel: therapeutic effects on malignant pleural effusion","volume":"3","author":"Fang","year":"2009","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104717_bib36","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1002\/jcp.27782","article-title":"CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review","volume":"234","author":"Farhood","year":"2019","journal-title":"J. Cell Physiol."},{"issue":"S1","key":"10.1016\/j.critrevonc.2025.104717_bib37","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104717_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2024.122031","article-title":"Protein-assisted synthesis of chitosan-coated minicells enhance dendritic cell recruitment for therapeutic immunomodulation within pulmonary tumors","volume":"334","author":"Feng","year":"2024","journal-title":"Carbohydr. Polym."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104717_bib39","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/j.chest.2021.07.031","article-title":"Intrapleural hyaluronidase in viscous malignant mesothelioma pleural effusion","volume":"160","author":"Foo","year":"2021","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104717_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/cells11020222","article-title":"Plasmacytoid dendritic cells and cancer immunotherapy","volume":"11","author":"Fu","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib41","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.immuni.2019.12.018","article-title":"Tumor immunology and tumor evolution: intertwined histories","volume":"52","author":"Galon","year":"2020","journal-title":"Immunity"},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104717_bib42","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104717_bib43","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104717_bib44","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s41578-023-00581-x","article-title":"New opportunities and old challenges in the clinical translation of nanotheranostics","volume":"8","author":"Gawne","year":"2023","journal-title":"Nat. Rev. Mater."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104717_bib45","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccr.2013.01.008","article-title":"Role of macrophage targeting in the antitumor activity of trabectedin","volume":"23","author":"Germano","year":"2013","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib46","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1038\/s41598-020-62813-2","article-title":"Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition","volume":"10","author":"Ghanim","year":"2020","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104717_bib47","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/bjc.1995.501","article-title":"Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study","volume":"72","author":"Goey","year":"1995","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104717_bib48","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/1759-7714.13006","article-title":"Malignant pleural effusion supernatant is an alternative liquid biopsy specimen for comprehensive mutational profiling","volume":"10","author":"Guo","year":"2019","journal-title":"Thorac. Cancer"},{"issue":"474","key":"10.1016\/j.critrevonc.2025.104717_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat5690","article-title":"Autologous tumor cell-derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion","volume":"11","author":"Guo","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104717_bib50","first-page":"3940","article-title":"Clinical efficacy of intra-cavitary infusions of autologous dendritic cell\/cytokine-induced killer cell products for the treatment of refractory malignant pleural effusions and ascites","volume":"12","author":"He","year":"2020","journal-title":"Am. J. Transl. Res"},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104717_bib51","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104717_bib52","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104717_bib53","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The tumor microenvironment innately modulates cancer progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104717_bib54","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.lungcan.2012.03.006","article-title":"VEGF and sVEGFR-1 in malignant pleural effusions: association with survival and pleurodesis outcomes","volume":"77","author":"Hooper","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2025.104717_bib55","doi-asserted-by":"crossref","first-page":"8281718","DOI":"10.1155\/2021\/8281718","article-title":"Oleanolic acid induces autophagy and apoptosis via the AMPK-mTOR signaling pathway in colon cancer","volume":"2021","author":"Hu","year":"2021","journal-title":"J. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104717_bib56","doi-asserted-by":"crossref","first-page":"e930","DOI":"10.1016\/S2352-3026(22)00291-5","article-title":"CAR T-cell therapies in China: rapid evolution and a bright future","volume":"9","author":"Hu","year":"2022","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104717_bib57","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ymthe.2023.12.012","article-title":"Irradiated engineered tumor cell-derived microparticles remodel the tumor immune microenvironment and enhance antitumor immunity","volume":"32","author":"Hu","year":"2024","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib58","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1038\/s41467-021-27026-9","article-title":"Single-cell analysis of diverse immune phenotypes in malignant pleural effusion","volume":"12","author":"Huang","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib59","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1038\/s41467-021-27026-9","article-title":"Single-cell analysis of diverse immune phenotypes in malignant pleural effusion","volume":"12","author":"Huang","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib60","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1038\/s41467-021-27026-9","article-title":"Single-cell analysis of diverse immune phenotypes in malignant pleural effusion","volume":"12","author":"Huang","year":"2021","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104717_bib61","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.trecan.2016.09.007","article-title":"Immune priming of the tumor microenvironment by radiation","volume":"2","author":"Jiang","year":"2016","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib62","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s40425-019-0573-5","article-title":"STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models","volume":"7","author":"Jing","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib63","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1038\/s41467-018-06922-7","article-title":"Structural insights into cGAMP degradation by Ecto-nucleotide pyrophosphatase phosphodiesterase 1","volume":"9","author":"Kato","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib64","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10637-019-00882-5","article-title":"Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study","volume":"38","author":"Kawachi","year":"2020","journal-title":"Invest N. Drugs"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104717_bib65","article-title":"Efficacy of immune checkpoint inhibitor with or without chemotherapy for nonsquamous NSCLC with malignant pleural effusion: a retrospective multicenter cohort study","volume":"3","author":"Kawachi","year":"2022","journal-title":"JTO Clin. Res Rep."},{"key":"10.1016\/j.critrevonc.2025.104717_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121917","article-title":"Theranostic chimeric antigen receptor (CAR)-T cells: insight into recent trends and challenges in solid tumors","volume":"328","author":"Kheyrolahzadeh","year":"2023","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.5483\/BMBRep.2021.54.1.224","article-title":"The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets","volume":"54","author":"Kim","year":"2021","journal-title":"BMB Rep."},{"issue":"35","key":"10.1016\/j.critrevonc.2025.104717_bib68","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized Phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104717_bib69","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-88-4-532","article-title":"Pleural effusion from malignancy","volume":"88","author":"Leff","year":"1978","journal-title":"Ann. Intern Med."},{"key":"10.1016\/j.critrevonc.2025.104717_bib70","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2025.104717_bib71","doi-asserted-by":"crossref","unstructured":"Li, C., et al., Regulatory T cells in tumor microenvironment: new mechanisms, potentia l therapeutic strategies and future prospects. Molecular Cancer. 19(1).","DOI":"10.1186\/s12943-020-01234-1"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104717_bib72","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nchembio.1661","article-title":"Hydrolysis of 2\u20323'-cGAMP by ENPP1 and design of nonhydrolyzable analogs","volume":"10","author":"Li","year":"2014","journal-title":"Nat. Chem. Biol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104717_bib73","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/ijc.30289","article-title":"Impaired T cell function in malignant pleural effusion is caused by TGF-\u03b2 derived predominantly from macrophages","volume":"139","author":"Li","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104717_bib74","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/ijc.30289","article-title":"Impaired T cell function in malignant pleural effusion is caused by TGF-\u03b2 derived predominantly from macrophages","volume":"139","author":"Li","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104717_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.760683","article-title":"Intrapleural injection of anti-PD1 antibody: a novel management of malignant pleural effusion","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104717_bib76","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cytogfr.2023.06.005","article-title":"Exosomes: another intercellular lipometabolic communication mediators in digestive system neoplasms?","volume":"73","author":"Li","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"issue":"Pt 2","key":"10.1016\/j.critrevonc.2025.104717_bib77","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.semcancer.2022.09.005","article-title":"Unraveling tumor microenvironment of small-cell lung cancer: implications for immunotherapy","volume":"86","author":"Li","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104717_bib78","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1164\/rccm.201310-1776OC","article-title":"Interplay of Th1 and Th17 cells in murine models of malignant pleural effusion","volume":"189","author":"Lin","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104717_bib79","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1164\/rccm.201310-1776OC","article-title":"Interplay of Th1 and Th17 cells in murine models of malignant pleural effusion","volume":"189","author":"Lin","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104717_bib80","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104717_bib81","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41565-021-01032-w","article-title":"Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion","volume":"17","author":"Liu","year":"2022","journal-title":"Nat. Nanotechnol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104717_bib82","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41565-021-01032-w","article-title":"Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion","volume":"17","author":"Liu","year":"2022","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib83","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13046-019-1153-8","article-title":"Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment","volume":"38","author":"Looi","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"10336","key":"10.1016\/j.critrevonc.2025.104717_bib84","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104717_bib85","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/cr.2016.53","article-title":"Reversing drug resistance of soft tumor-repopulating cells by tumor cell-derived chemotherapeutic microparticles","volume":"26","author":"Ma","year":"2016","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib86","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41392-022-01198-2","article-title":"A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis","volume":"7","author":"Ma","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib87","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/s41467-023-37225-1","article-title":"Modular-designed engineered bacteria for precision tumor immunotherapy via spatiotemporal manipulation by magnetic field","volume":"14","author":"Ma","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104717_bib88","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","article-title":"The emerging field of oncolytic virus-based cancer immunotherapy","volume":"9","author":"Ma","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2025.104717_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2025.102745","article-title":"Curculigoside exhibits multiple therapeutic ef\ufb01cacy to induce apoptosis and ferroptosis in osteosarcoma via modulation of ROS and tumor microenvironment","volume":"93","author":"Ma","year":"2025","journal-title":"Tissue Cell"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104717_bib90","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104717_bib91","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.coi.2010.01.009","article-title":"Macrophages, innate immunity and cancer: balance, tolerance, and diversity","volume":"22","author":"Mantovani","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104717_bib92","doi-asserted-by":"crossref","unstructured":"Marjani, A.A., N.D. Nader, and A. Aghanejad, Exosomes as Targeted Diagnostic Biomarkers: Recent Studies and Trends. Life Sciences. 354: p. 122985.","DOI":"10.1016\/j.lfs.2024.122985"},{"key":"10.1016\/j.critrevonc.2025.104717_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122985","article-title":"Exosomes as targeted diagnostic biomarkers: recent studies and trends","volume":"354","author":"Marjani","year":"2024","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104717_bib94","first-page":"ii32","article-title":"Management of a malignant pleural effusion: british thoracic society pleural disease guideline 2010","volume":"65","author":"Mark","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.critrevonc.2025.104717_bib95","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fphys.2014.00221","article-title":"Tight junction physiology of pleural mesothelium","volume":"5","author":"Markov","year":"2014","journal-title":"Front. Physiol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib96","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009930","article-title":"Arginase-1-specific T cells target and modulate tumor-associated macrophages","volume":"13","author":"Martinenaite","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104717_bib97","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1158\/2326-6066.CIR-13-0102","article-title":"Dendritic cells: master regulators of the immune response","volume":"1","author":"Mellman","year":"2013","journal-title":"Cancer Immunol. Res"},{"issue":"7378","key":"10.1016\/j.critrevonc.2025.104717_bib98","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104717_bib99","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1097\/JTO.0b013e318267223a","article-title":"Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer","volume":"7","author":"Morgensztern","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib100","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK cells and cancer: you can teach innate cells new tricks","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104717_bib101","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/nri2448","article-title":"Exploring the full spectrum of macrophage activation","volume":"8","author":"Mosser","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104717_bib102","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1554969","article-title":"Making cold malignant pleural effusions hot: driving novel immunotherapies","volume":"8","author":"Murthy","year":"2019","journal-title":"Oncoimmunology"},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104717_bib103","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24224192","article-title":"ENPP1, an old enzyme with new functions, and small molecule inhibitors-a sting in the tale of ENPP1","volume":"24","author":"Onyedibe","year":"2019","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104717_bib104","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00262-010-0855-8","article-title":"Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity","volume":"59","author":"Ostrand-Rosenberg","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104717_bib105","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejca.2010.09.001","article-title":"Altered CD94\/NKG2A and perforin expression reduce the cytotoxic activity in malignant pleural effusions","volume":"47","author":"Pace","year":"2011","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104717_bib106","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"433","key":"10.1016\/j.critrevonc.2025.104717_bib107","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar1916","article-title":"Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases","volume":"10","author":"Park","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104717_bib108","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.3390\/cancers12113445","article-title":"Complications after CD19+ CAR T-cell therapy","volume":"12","author":"Penack","year":"2020","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104717_bib109","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.4049\/jimmunol.178.5.2763","article-title":"Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage","volume":"178","author":"Perrot","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104717_bib110","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1186\/1471-2407-12-615","article-title":"Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)","volume":"12","author":"Petrausch","year":"2012","journal-title":"BMC Cancer"},{"issue":"140","key":"10.1016\/j.critrevonc.2025.104717_bib111","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1183\/16000617.0019-2016","article-title":"Malignant pleural effusion: from bench to bedside","volume":"25","author":"Psallidas","year":"2016","journal-title":"Eur. Respir. Rev."},{"issue":"140","key":"10.1016\/j.critrevonc.2025.104717_bib112","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1183\/16000617.0019-2016","article-title":"Malignant pleural effusion: from bench to bedside","volume":"25","author":"Psallidas","year":"2016","journal-title":"Eur. Respir. Rev."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104717_bib113","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1158\/1078-0432.CCR-08-2641","article-title":"CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion","volume":"15","author":"Qin","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"6382","key":"10.1016\/j.critrevonc.2025.104717_bib114","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104717_bib115","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104717_bib116","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2125.2010.03635.x","article-title":"Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients","volume":"69","author":"Ruf","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.critrevonc.2025.104717_bib117","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/1471-2407-13-324","article-title":"Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid","volume":"13","author":"Scherpereel","year":"2013","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104717_bib118","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.4049\/jimmunol.1201018","article-title":"Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth","volume":"189","author":"Schlecker","year":"2012","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104717_bib119","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41565-018-0342-5","article-title":"Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy","volume":"14","author":"Shae","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.critrevonc.2025.104717_bib120","doi-asserted-by":"crossref","first-page":"1161375","DOI":"10.3389\/fimmu.2023.1161375","article-title":"Macrophage-derived exosome promotes regulatory T cell differentiation in malignant pleural effusion","volume":"14","author":"Shao","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104717_bib121","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cytogfr.2024.08.001","article-title":"Targeting PD-1\/PD-L1 in tumor immunotherapy: mechanisms and interactions with host growth regulatory pathways","volume":"79","author":"Shen","year":"2024","journal-title":"Cytokine Growth Factor Rev."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104717_bib122","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/1759-7714.13004","article-title":"Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer","volume":"10","author":"Shibaki","year":"2019","journal-title":"Thorac. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104717_bib123","doi-asserted-by":"crossref","first-page":"977","DOI":"10.4049\/jimmunol.179.2.977","article-title":"Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response","volume":"179","author":"Sinha","year":"2007","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104717_bib124","doi-asserted-by":"crossref","first-page":"977","DOI":"10.4049\/jimmunol.179.2.977","article-title":"Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response","volume":"179","author":"Sinha","year":"2007","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104717_bib125","article-title":"Translational nanotherapeutics reprograms immune microenvironment in malignant pleural effusion of lung adenocarcinoma","volume":"10","author":"Song","year":"2021","journal-title":"Adv. Health Mater."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104717_bib126","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104717_bib127","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1136\/gutjnl-2013-306271","article-title":"Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity","volume":"63","author":"Stromnes","year":"2014","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104717_bib128","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2018.09.007","article-title":"Immune checkpoint inhibition overcomes ADCP-induced immunosuppression by macrophages","volume":"175","author":"Su","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104717_bib129","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00262-024-03890-4","article-title":"Efficacy and safety of nivolumab and ipilimumab with or without chemotherapy for unresectable non-small cell lung cancer: a multicenter retrospective observational study","volume":"74","author":"Sumi","year":"2025","journal-title":"Cancer Immunol., Immunother."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104717_bib130","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1016\/j.biomaterials.2009.03.022","article-title":"A chitosan-dipotassium orthophosphate hydrogel for the delivery of Doxorubicin in the treatment of osteosarcoma","volume":"30","author":"Ta","year":"2009","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104717_bib131","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.chest.2016.11.010","article-title":"US hospitalizations for malignant pleural effusions: data from the 2012 National inpatient sample","volume":"151","author":"Taghizadeh","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.critrevonc.2025.104717_bib132","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/ncomms2282","article-title":"Delivery of chemotherapeutic drugs in tumour cell-derived microparticles","volume":"3","author":"Tang","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104717_bib133","series-title":"Nanostructured Materials","first-page":"1","article-title":"Nanotechnology and dimensions","author":"Thangadurai","year":"2020"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104717_bib134","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non\u2013small cell lung cancer: results of the PEMBRO-RT Phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104717_bib135","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.chest.2016.01.001","article-title":"Longitudinal measurement of pleural fluid biochemistry and cytokines in malignant pleural effusions","volume":"149","author":"Thomas","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.critrevonc.2025.104717_bib136","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-3-030-37184-5_2","article-title":"Fibroblasts in the tumor microenvironment","volume":"1234","author":"Truffi","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104717_bib137","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jtho.2017.10.034","article-title":"PD-L1 expression of tumor cells, macrophages, and immune cells in non-small cell lung cancer patients with malignant pleural effusion","volume":"13","author":"Tseng","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104717_bib138","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25021180","article-title":"Oncolytic virotherapy: a new paradigm in cancer immunotherapy","volume":"25","author":"Volovat","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104717_bib139","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccell.2018.03.008","article-title":"The immune revolution: a case for priming, not checkpoint","volume":"33","author":"Vonderheide","year":"2018","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104717_bib140","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104717_bib141","doi-asserted-by":"crossref","first-page":"eaay9789","DOI":"10.1126\/sciadv.aay9789","article-title":"Irradiated tumor cell-derived microparticles mediate tumor eradication via cell killing and immune reprogramming","volume":"6","author":"Wan","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2025.104717_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2021.101323","article-title":"Peptide hydrogels loaded with irradiated tumor cell secretions enhance cancer immunotherapy","volume":"41","author":"Wan","year":"2021","journal-title":"Nano Today"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104717_bib143","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00262-015-1701-9","article-title":"CD163+CD14+\u2009macrophages, a potential immune biomarker for malignant pleural effusion","volume":"64","author":"Wang","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2025.104717_bib144","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.canlet.2019.03.040","article-title":"Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion","volume":"452","author":"Wang","year":"2019","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib145","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-024-02214-5","article-title":"Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges","volume":"24","author":"Wang","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib146","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40425-019-0565-5","article-title":"Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen","volume":"7","author":"Wculek","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib147","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/s12885-024-12173-1","article-title":"Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study","volume":"24","author":"Wei","year":"2024","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104717_bib148","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2025.104717_bib149","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3389\/fcell.2020.00812","article-title":"MicroRNA: another pharmacological avenue for colorectal cancer?","volume":"8","author":"Wu","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104717_bib150","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00262-020-02781-8","article-title":"The M1\/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer","volume":"70","author":"Wu","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2025.104717_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107521","article-title":"EVA1B facilitates esophageal squamous carcinoma progression and recruitment of immunosuppressive myeloid-derived suppressor cells in the tumor microenvironment","volume":"210","author":"Xia","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104717_bib152","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.7150\/thno.67775","article-title":"Tumor-derived extracellular vesicles as messengers of natural products in cancer treatment","volume":"12","author":"Xu","year":"2022","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib153","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-023-00373-7","article-title":"Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment","volume":"12","author":"Yan","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104717_bib154","first-page":"2885","article-title":"Efficacy of intrapleural injection of recombinant human type 5 adenovirus in the treatment of malignant pleural effusion in advanced lung cancer","volume":"29","author":"Yang","year":"2013","journal-title":"J. Pract. Med."},{"issue":"7669","key":"10.1016\/j.critrevonc.2025.104717_bib155","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nature23665","article-title":"Homeostatic control of metabolic and functional fitness of T(reg) cells by LKB1 signalling","volume":"548","author":"Yang","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib156","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12890-015-0025-z","article-title":"Important prognostic factors for survival in patients with malignant pleural effusion","volume":"15","author":"Zamboni","year":"2015","journal-title":"BMC Pulm. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104717_bib157","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-15-1849","article-title":"Reversing T-cell dysfunction and exhaustion in cancer","volume":"22","author":"Zarour","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104717_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2022.108104","article-title":"Local sustained release of PD-1 monoclonal antibody and lenvatinib by thermo-sensitive hydrogel for improving tumor immunotherapy","volume":"34","author":"Zhai","year":"2023","journal-title":"Chin. Chem. Lett."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104717_bib159","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1072","article-title":"Characterization of the tumour microenvironment phenotypes in malignant tissues and pleural effusion from advanced osteoblastic osteosarcoma patients","volume":"12","author":"Zhang","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.critrevonc.2025.104717_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106777","article-title":"Research progress on the interaction between oxidative stress and platelets: Another avenue for cancer?","volume":"191","author":"Zhang","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104717_bib161","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/cam4.5005","article-title":"Research progress of tumor-derived extracellular vesicles in the treatment of malignant pleural effusion","volume":"12","author":"Zhang","year":"2023","journal-title":"Cancer Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104717_bib162","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007441","article-title":"C1q(+) tumor-associated macrophages contribute to immunosuppression through fatty acid metabolic reprogramming in malignant pleural effusion","volume":"11","author":"Zhang","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104717_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155458","article-title":"M2 macrophages promote PD-L1 expression in triple-negative breast cancer via secreting CXCL1","volume":"260","author":"Zhang","year":"2024","journal-title":"Pathol. Res Pract."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104717_bib164","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s10637-024-01424-4","article-title":"First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?","volume":"42","author":"Zhao","year":"2024","journal-title":"Invest N. Drugs"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104717_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.engmic.2022.100034","article-title":"Engineered bacteria as drug delivery vehicles: principles and prospects","volume":"2","author":"Zhou","year":"2022","journal-title":"Eng. Microbiol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104717_bib166","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12943-019-1087-y","article-title":"STING: a master regulator in the cancer-immunity cycle","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:37:40Z","timestamp":1778794660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825001052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":166,"alternative-id":["S1040842825001052"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104717","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel bioengineered drugs with immunotherapies for malignant pleural effusion: Remodulate tumor immune microenvironment and activate immune system","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104717"}}